Nadroparin

Nadroparin

Clinical data
ATC code	B01AB06 (WHO)
Identifiers
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Molar mass	Mean MW = 4500 Daltons

WikiDoc Resources for Nadroparin
Articles
Most recent articles on Nadroparin Most cited articles on Nadroparin Review articles on Nadroparin Articles on Nadroparin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Nadroparin Images of Nadroparin Photos of Nadroparin Podcasts & MP3s on Nadroparin Videos on Nadroparin
Evidence Based Medicine
Cochrane Collaboration on Nadroparin Bandolier on Nadroparin TRIP on Nadroparin
Clinical Trials
Ongoing Trials on Nadroparin at Clinical Trials.gov Trial results on Nadroparin Clinical Trials on Nadroparin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Nadroparin NICE Guidance on Nadroparin NHS PRODIGY Guidance FDA on Nadroparin CDC on Nadroparin
Books
Books on Nadroparin
News
Nadroparin in the news Be alerted to news on Nadroparin News trends on Nadroparin
Commentary
Blogs on Nadroparin
Definitions
Definitions of Nadroparin
Patient Resources / Community
Patient resources on Nadroparin Discussion groups on Nadroparin Patient Handouts on Nadroparin Directions to Hospitals Treating Nadroparin Risk calculators and risk factors for Nadroparin
Healthcare Provider Resources
Symptoms of Nadroparin Causes & Risk Factors for Nadroparin Diagnostic studies for Nadroparin Treatment of Nadroparin
Continuing Medical Education (CME)
CME Programs on Nadroparin
International
Nadroparin en Espanol Nadroparin en Francais
Business
Nadroparin in the Marketplace Patents on Nadroparin
Experimental / Informatics
List of terms related to Nadroparin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Nadroparin is a form of low molecular weight heparin.

External Links

• http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128
• http://www.mayoclinic.com/health/drug-information/DR600971
• Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology. 78 (3): 136–43. doi:10.1159/000096484. PMID 17057417.CS1 maint: Multiple names: authors list (link)